Elevated cerebrospinal fluid and plasma levels of Tumor Necrosis Factor-alpha (TNFa) and Interleukin-6 (IL-6) in AD patients [17] predict further cognitive decline [18] and have been linked to worse cognitive performance in both MCI and AD patients [19]. The gene discussed is IL6; the disease is Alzheimer disease.